apoB/apoA-I Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPIC-Norfolk Prospective Population Study

Kang H. Zheng, MD; Benoit J.Arsenault, PhD; Yannick Kaiser, MD; Kay-Tee Khaw, MBBCChir; Nicholas J. Wareham, MBBS, PhD; Erik S. G. Stroes, MD, PhD; S. Matthijs Boekholdt, MD, PhD

Background—Apolipoprotein B/apolipoprotein A-I (apoB/apoA-I) ratio and lipoprotein(a) (Lp[a]) are associated with aortic valve stenosis (AVS) disease progression. Clinical characteristics such as age, sex, and presence of concomitant coronary artery disease may strongly modify these associations; however, these effects have not been well defined in longitudinal studies. We set out to assess these associations between apoB/apoA-I ratio, Lp(a), and AVS incidence in a large population study.

Methods and Results—We analyzed data from 17 745 participants (mean age, 59.2±9.1 years; men, 44.9%) in the EPIC-Norfolk (European Prospective Investigation Into Cancer in Norfolk Prospective Population Study) population study in whom apoB/apoA-I and Lp(a) levels were measured. Participants were identified as having incident AVS if they were hospitalized or died with AVS as an underlying cause. After a median follow-up of 19.8 years (17.9–21.0 years) there were 403 (2.2%) incident cases of AVS. The hazard ratio for AVS risk was 1.30 (95% CI, 1.19–1.41; \(P=0.001\)) per SD increase in apoB/apoA-I. Adjusting for age, sex, and coronary artery disease, there was no significant association between apoB/apoA-I and AVS incidence (hazard ratio, 1.06; 95% CI, 0.97–1.17 \(P=0.215\)). Elevated Lp[a] (>50 mg/dL) remained an independent risk factor for AVS after adjustment for age, sex, low-density lipoprotein cholesterol, and concomitant coronary artery disease (hazard ratio, 1.70; 95% CI, 1.33–2.19 \(P<0.001\)).

Conclusions—in this population study, apoB/apoA-I ratio was associated with risk of AVS incidence, especially in younger and female participants and those without concomitant coronary artery disease. Lp(a) was an independent risk factor for AVS incidence. Interventional trials are needed to investigate whether modulating apoB/apoA-I or lowering Lp(a) can prevent or slow down AVS. (J Am Heart Assoc. 2019;8:e013020. DOI: 10.1161/JAHA.119.013020.)

Key Words: aortic valve stenosis • apoB/apoA-I ratio • lipids and lipoproteins • lipoprotein(a) • low-density lipoprotein cholesterol

Atherogenic apolipoprotein B (apoB)–containing lipoproteins such as low-density lipoprotein (LDL) and lipoprotein (a) (Lp[a]) have clearly been implicated in the pathogenesis of aortic valve stenosis (AVS).\(^1,2\) However, trials aimed at reducing LDL cholesterol (LDL-C) with statins and ezetimibe have failed to document a significant reduction in AVS progression\(^3\) and Lp (a)-targeted trials have yet to be performed, currently leaving clinicians with no proven medical therapy to reduce disease progression.

A recent Swedish case-control study reported that apoB/apolipoprotein A-I (apoB-apoA-I) and Lp(a) were associated with future AVS surgery in patients with concomitant coronary artery disease (CAD) but not in those with “isolated” AVS.\(^4\) These findings suggested that patients with AVS could have different phenotypes, in which risk factors such as atherogenic lipoproteins may or may not play a major role in driving disease progression. In addition, post hoc analyses of the PROGRESSA (Metabolic Determinants of the Progression of Aortic Stenosis) trial\(^5\) found that apoB/apoA-I was associated with faster hemodynamic progression in patients with mild to moderate AVS. These effects appeared especially pronounced in the younger subset of patients, suggesting that...
lipoprotein-mediated pathology is dominant in younger patients, while other risk factors may contribute more to disease progression in elderly patients.

Risk factors for AVS progression can differ from those associated with AVS incidence as a result of underlying differences in pathophysiology in the initiation and propagation stages of disease. Large longitudinal cohorts are needed to assess whether and in whom these risk factors could be viable for intervention or risk stratification. It is unknown whether apoB/apoA-I ratio is associated with AVS incidence in the general population. Whether the associations between apoB/apoA-I ratio, Lp(a), and AVS incidence are independent of presence of CAD is also unknown.

The goal of this study was 2-fold: (1) to assess the associations between apoB/apoA-I ratio, Lp(a), and AVS incidence in a prospective, longitudinal study, and (2) to evaluate how clinical characteristics modify these associations. These data could have important implications for the design of future randomized trials to evaluate novel lipid-lowering therapies, as well for individual risk assessment or treatment of patients with AVS.

Methods

EPIC-Norfolk (European Prospective Investigation Into Cancer in Norfolk Prospective Population Study) data will not be made publicly available for purposes of reproducing the results. Procedures to request access to EPIC-Norfolk data can be found online (http://www.srl.cam.ac.uk/epic/).

EPIC-Norfolk Population Study

The EPIC-Norfolk was a prospective population study of 25 639 male and female inhabitants of Norfolk, United Kingdom, aged between 39 and 79 years. The design and methods of EPIC-Norfolk have been previously described in detail. Data were collected from February 1993 through March 2016. The primary outcome was AVS. Participants were identified as having incident AVS if they were hospitalized with AVS (International Classification of Diseases, Tenth Revision [ICD-10] code I35) as an underlying cause or if they died with AVS as an underlying cause. We defined the presence of concomitant CAD as self-reporting a history of prevalent CAD at baseline or first incident CAD during follow-up (ICD-10 code I20–25). The Norwich District Health Authority Ethics Committee approved the study, and all participants gave signed informed consent.

Laboratory Measurements

Conventional lipid profiles were measured at baseline as previously described. LDL-C was calculated using the Friedewald formula. ApoB and apoA-I were measured using rate immunonephelometry (Behring Nephelometer BNII). Lp(a) levels were measured in baseline samples (stored frozen at −80°C for ≈15 years) with an immunoturbidimetric assay using polyclonal antibodies directed against epitopes in apolipoprotein(a) (Denka Seiken) as previously described.

Statistical Analyses

For this prospective analysis, study participants were excluded if apoB, apoA-I, or Lp(a) levels were missing. Baseline characteristics and lipid measurements were compared between participants who developed AVS during follow-up versus those who did not with the unpaired Student t test. Cox regression analysis was used to calculate hazard ratios (HRs) and corresponding 95% CIs for the time to hospitalization or death because of AVS. Statistical analyses were performed using SPSS software version 25 (SPSS Inc).

Results

Complete data were available in 17 745 participants (mean age 59.2±9.1 years; male 44.9%) (Table). At baseline, 579 participants reported a history of CAD and 3300 participants reported a first incident event of CAD during follow-up. After a median follow-up of 19.8 years (17.9–21.0 years), there were 403 (2.2%) incident cases of AVS. The associations between apoB/apoA-I, Lp(a), and risk of incident AVS are shown in Figure.

The mean apoB/apoA-I ratio was higher among cases than among controls (0.70±0.19 versus 0.64±0.19; P=0.001). In the entire study cohort, the HR for AVS risk was 1.30 (95% CI,
1.19–1.41) per SD increase in apoB/apoA-I. After adjusting for age and sex, this relationship was attenuated (HR, 1.18; 95% CI, 1.07–1.30 [P=0.001]). Notably, after additional adjustment for concomitant CAD, there was no significant association between apoB/apoA-I and AVS incidence (HR, 1.06; 95% CI, 0.97–1.17 [P=0.215]). The risk of AVS stratified per apoB/apoA-I quartile is documented in Figure S1.

We further investigated these findings by analyzing apoB/apoA-I ratio and stratifying by age, sex, or concomitant CAD. In younger participants (median age, ≤59 years) the HR for AVS risk was 1.28 (95% CI, 1.05–1.56; P=0.014) for each SD increase in apoB/apoA-I, whereas this appeared slightly lower in older participants (>59 years; HR, 1.20 [95% CI, 1.08–1.33]; P=0.001). In even older participants (>67 years, top
apoB/apoA-I, Lp(a), and AVS Incidence – sexes, we found a stronger association for apoB/apoA-I ratio and AVS risk in women (HR, 1.39; 95% CI, 1.23–1.58 \[P<0.001\]) compared with men (HR, 1.16; 95% CI, 1.02–1.32 \[P=0.025\]). Stratifying for CAD, we found that apoB/apoA-I ratio was associated with a higher risk in patients without concomitant CAD (HR, 1.20; 95% CI, 1.02–1.40 \[P=0.025\]), compared with participants with CAD (HR, 1.02; 95% CI, 0.91–1.14 \[P=0.78\]). These findings were further supported when we tested apoB/apoA-I for interactions with age older than 67 years \(P=0.001\), sex \(P=0.045\), and concomitant CAD \(P=0.075\). Age as a continuous variable did not reach statistical significance as an interaction term \(P=0.190\).

In secondary analyses, we corrected apoB for its contribution in Lp(a). The associations between corrected apoB/apoA-I and AVS incidence were slightly attenuated compared with uncorrected apoB/apoA-I, but overall results were similar (Table S1, Figure S2).

Previously, we reported the independent associations between elevated levels of Lp(a) \(\geq50\) mg/dL and risk of incident AVS, after adjustment for age, sex, and LDL-C. Additional adjustment for concomitant CAD did not markedly impact this relationship (HR, 1.99; 95% CI, 1.55–2.56 \[P<0.001\] versus CAD adjusted HR, 1.70; 95% CI, 1.33–2.19 \[P<0.001\]). Stratification by quartiles revealed that the risk for AVS clearly begins to increase in the top quartile \(\geq28\) mg/dL (Figure S1). The HRs per each unit increase of natural log-transformed Lp(a) levels, stratified by the presence of concomitant CAD were also similar (no CAD HR, 1.17; 95% CI, 0.99–1.38 \[P=0.06\] versus CAD HR, 1.19; 95% CI, 1.05–1.34 \[P=0.006\]).

Elevated Lp(a) has been suggested to synergistically increase CAD risk in patients with elevated LDL-C. To investigate this concept for AVS risk, we stratified for elevated LDL-C and compared the HRs per each unit increase of natural-log transformed Lp(a) (Table S2). Lp(a) levels appeared to confer more risk in patients with elevated LDL-C between \(160\) mg/dL and \(190\) mg/dL (HR, 1.56; 95% CI, 1.29–1.90 \[P=0.001\]) compared with patients with LDL-C <160 mg/dL (HR, 1.22; 95% CI, 1.06–1.40 \[P=0.006\]). However, this was not the case in patients with even higher LDL-C \(\geq190\) mg/dL (HR, 1.178; 95% CI, 0.940–1.477 \[P=0.154\]). We did not find a statistical significant interaction between corrected apoB/apoA-I ratio and natural log-transformed Lp(a) levels \(P=0.916\).

**Discussion**

The apoB/apoA-I ratio is considered to reflect the balance between atherogenic apoB-containing particles and antiatherogenic high-density lipoprotein particles. As such, this metric captures both dyslipidemia and dysmetabolic regulation. In our population study, apoB/apoA-I ratio was found to be a strong predictor of AVS incidence, especially in younger and female participants. These findings support the concept that lipoproteins are involved in the pathogenesis of AVS, and are also compatible with the failure of previous statin trials to reduce AVS progression by LDL-C lowering. Because these trials included mostly older (and male) patients with AVS, disease may have been too advanced to be amenable to lipid-lowering therapy, suggesting that LDL or apoB-containing particles play a predominant role in early stages of disease but are less important with increasing disease severity. Our observation that apoB/apoA-I ratio was a stronger risk predictor in women compared with men is in line with emerging clinical data on sex-related differences in AVS pathogenesis. Recent studies showed that women needed less valvular calcium burden than men to develop severe AVS, while women also demonstrated differential left ventricular remodeling and earlier symptom onset in AVS compared with men. Collectively, these data highlight the need for further studies to advance our understanding of sex differences in AVS pathogenesis to ultimately improve clinical management.

In contrast to an earlier report by Ljungberg and colleagues, we found that the apoB/apoA-I ratio–associated risk of AVS incidence was higher in participants without concomitant CAD compared with those with CAD. Considering AVS shares many other risk factors with atherosclerosis, participants with CAD may also already have established subclinical AVS, at which stage increased apoB/apoA-I may not confer any additional risk for AVS incidence. Interestingly, Lp(a) levels persisted as a risk factor in nearly all tested subgroups—including patients with concomitant CAD—suggesting that perhaps the oxidized phospholipids or other moiety on the Lp(a) particle act via different pathways than other apoB-containing lipoproteins. These findings are in line with a recent multimodality imaging study in which elevated Lp(a) and oxidized phospholipids on apoB were associated with faster disease progression independent of concomitant CAD. Furthermore, a secondary analysis of the ASTRONOMER (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin) study, which excluded patients with concomitant CAD, demonstrated that elevated Lp(a) and oxidized phospholipids on apoB were associated with faster hemodynamic progression and need for valve replacement. In the setting of elevated LDL-C, Lp(a) was associated with an additional risk of AVS incidence, although this was not clear in patients with severe hypercholesterolemia (LDL-C \(\geq190\) mg/dL). This group likely includes patients with a familial hypercholesterolemia phenotype, in whom AVS risk is increased such that the contribution of Lp(a) is relatively small, or perhaps that patients die of atherosclerotic disease before any AVS diagnosis can be made.
Clinical trials investigating novel therapies are needed to determine whether modulating the apoB/apoA-I ratio or lowering Lp(a) can prevent or slow disease progress in AVS. Previous clinical studies have established that PCSK9 inhibitors are able to reduce both LDL-C and Lp(a). In addition, the PCSK9 R46L loss-of-function mutation is associated with reduced risk of AVS and myocardial infarction. Recently, experimental data suggested that PCSK9 may also directly facilitate calcification in valvular interstitial cells. Taken together, PCSK9 inhibition therapy could potentially reduce AVS disease progression and valve-related events. To our knowledge, only 1 clinical trial is currently registered that aims to test this hypothesis (NCT03051360). Antisense oligonucleotides against apolipoprotein(a) have been demonstrated to effectively reduce Lp(a) levels, and a phase III cardiovascular outcomes trial is being planned. A dedicated antisense trial will be needed to test the Lp(a) hypothesis in patients with AVS.

Study Limitations
Our study is observational and limited by defining AVS outcome based on ICD-10-coded hospitalizations and mortality. In this respect, the diagnosis of AVS was not standardized. However, a large medical records study has recently reported that this ICD-10 approach resulted in high diagnostic accuracy (>90%) in Sweden, but also restricted outcome to moderate to severe AVS cases.

Conclusions
In the EPIC-Norfolk population study, apoB/apoA-I ratio was associated with risk of AVS incidence, especially in younger and female participants and those without concomitant CAD. Lp(a) was an independent risk factor for AVS incidence.

Acknowledgments
The authors wish to thank the participants and staff of the EPIC-Norfolk prospective population study.

Disclosures
B. J. A. holds a junior scholar award from the Fondation de recherche du Québec: Santé. He has received research funding from the Canadian Institutes of Health Research, Pfizer, Merck, and Ionis Pharmaceuticals and is a consultant for Novartis. M. B. has served on the advisory boards of Pfizer and Sanofi. E. S. G. S.’ institution has received fees from lectures and advisory board participation from Amgen, Regeneron, Sanofi, Merck, Ionis, Chiesi, Akcea, Uniqor, and Athera. The remaining authors have no disclosures to report.

References
1. Smith JG, Luk K, Schulz CA, Engert JC, Do R, Hindy G, Rukh G, Dufresne L, Almgren P, Owens DS, Harris TB, Peloso GM, Kerr KF, Wong Q, Smith AV, Budoff MJ, Rotter JI, Cutillas LA, Rich S, Kathiresan S, Orho-Melander M, Gudnason V, O’Donnell CJ, Post WS, Thannousouls G, Cohorts for Heart and Aging Research in Genetic Epidemiology Extracoronary Calcium Working Group. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA. 2014;312:1764–1771.
2. Thannousouls G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, Malhotra R, O’Brien KD, Kamstrup PR, Nordestgaard BG, Tybjaerg-Hansen A, Allason MA, Aspuel S, Creager MA, Heckbert SR, Hwang SI, Liu Y, Siegmen van der Pals J, Kalisch H, Muhlesen TW, Nothen MM, Cupples LA, Caslake M, Di Angelantionio E, Danesh J, Rotter JI, Sigurdssons S, Wong Q, Erbel R, Kathiresan S, Melander O, Gudnason V, O’Donnell CJ, Post WS. CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–512.
3. Zhao Y, Nicoll R, He YH, Henein MY. The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis. Atherosclerosis. 2016;246:318–324.
4. Ljungberg J, Holmgren A, Bergdahl IA, Hultdin J, Norberg M, Naslund U, Johansson B, Soderberg S. Lipoprotein(a) and the apolipoprotein B/A1 ratio independently associated with surgery for aortic stenosis only in patients with concomitant coronary artery disease. J Am Heart Assoc. 2017;6:e007160. DOI: 10.1161/JAHA.117.007160.
5. Tastet L, Capoulae R, Shem M, Clavel MA, Cote N, Mathieu P, Arsenault M, Bedard E, Treblylajy, A, Samson M, Bosse Y, Dumesnil JG, Newby DE, Beaudoin J, Bernier M, Despres JP, Pigabarot P. ApoB/ApoA1 ratio is associated with faster hemodynamic progression of aortic stenosis: results from the PROGRESSA (metabolic determinants of the progression of aortic stenosis) study. J Am Heart Assoc. 2018;7:e008311. DOI: 10.1161/JAHA.117.008311.
6. Pawade TA, Newby DE, Dweck MR. Calcification in aortic stenosis: the skeleton key. J Am Coll Cardiol. 2015;66:561–577.
7. Day N, Oakes S, Luben R, Khat Bingham S, Welch A, Wareham N. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80(suppl 1):95–103.
8. Gurdasani D, Spuken B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, Pomilla C, Wareham NJ, Khat KT, Boekholdt SM, Sandhu MS. Lipoprotein(a) and risk of coronary, cerebral, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012;32:3058–3065.
9. Arsenault BJ, Boekholdt SM, Dube MP, Rheaume E, Wareham NJ, Khat KT, Sandhu MS, Tardif JC. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014;7:304–310.
10. Afshar M, Pirole M, Dufresne L, Engert JC, Thannousouls G. Lipoprotein(a) interactions with low-density lipoprotein cholesterol and other cardiovascular risk factors in premature acute coronary syndrome (ACS). J Am Heart Assoc. 2016;5:e003012. DOI: 10.1161/JAHA.115.003012.
11. Wallidius G, Jungner I. The apob/apoa-1 ratio: a strong new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. J Intern Med. 2006;259:493–519.
12. Dweck MR, Kwicinski J. Emerging sex differences in aortic stenosis. JACC Cardiovasc Imaging. 2019;12:106–108.
13. Aggarwal SR, Clavel MA, Messika-Zeitoun D, Cuffe C, Malouf J, Aavo PA, Mankaud R, Michelena H, Vahanian A, Enriquez-Sarano M. Sex differences in aortic valve calcification measured by multidetector computed tomography in aortic stenosis. Circ Cardiovasc Imaging. 2013;6:40–47.
14. Singh A, Chan DCS, Greenwood JP, Dawson DK, Soneckius P, Hogrefe K, Kelly DJ, Dhakshinamurthy V, Lang CC, Kho JP, Spriggins D, Steeds RP, Zhang R, Ford I, Jorscho-Verold M, Yang J, Li Z, Ng LL, McCann GP. Symptom onset in aortic stenosis: relation to sex differences in left ventricular remodeling. JACC Cardiovasc Imaging. 2019;12:106–108.
15. Zheng KH, Tsimikas S, Pawade T, Kroon J, Jenkins W, White AC, Timmers N, Hjortnaes J, Engert JC, Thanassoulis G; Cohorts for Heart and Aging Research in Genetic Epidemiology Extracoronary Calcium Working Group. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. J Am Coll Cardiol. 2019;73:2150–2162.
16. Capoulae R, Chan KL, Yang C, Mathieu P, Bosse Y, Dumesnil JG, Tan JW, Teo KK, Mahmut A, Yang X, Witztum JL, Arsenault BJ, Despres JP, Pigabarot P, Tsimikas S. Oxidized phospholipids, lipoprotein(a), and progression of aortic valve calcium. J Am Coll Cardiol. 2015;66:1236–1246.
17. O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Ceska R, Ezhov MV, Jukema
JW, Jensen HK, Tokgozoglu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. *Circulation*. 2019;139:1483–1492.

18. Langsted A, Nordestgaard BG, Benn M, Tybjaerg-Hansen A, Kamstrup PR. PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis. *J Clin Endocrinol Metab*. 2016;101:3281–3287.

19. Poggio P, Songia P, Cavallotti L, Barbieri SS, Zanotti I, Arsenault BJ, Valerio V, Ferri N, Capoulade R, Camera M. PCSK9 involvement in aortic valve calcification. *J Am Coll Cardiol*. 2018;72:3225–3227.

20. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. *Lancet*. 2016;388:2239–2253.

21. Vavilis G, Back M, Occhino G, Trevisan M, Bellocco R, Evans M, Lindholm B, Szummer K, Carrero JJ. Kidney dysfunction and the risk of developing aortic stenosis. *J Am Coll Cardiol*. 2019;73:305–314.
Supplemental Material
Table S1. Baseline apoB value corrected for its contribution in Lp(a).

| Variable                                      | Controls | Cases | p-value |
|-----------------------------------------------|----------|-------|---------|
| Secondary analyses                            |          |       |         |
| apoB corrected for Lp(a) mass                 | 94 ± 24  | 101 ± 25 | <0.001 |
| apoB corr. for \( \frac{Lp(a)\text{ mass}}{apoA-I} \) ratio | 0.62 ± 0.18 | 0.67 ± 0.19 | <0.001 |

ApoB was corrected for its contribution in Lp(a) using the following calculation: apoB corrected for Lp(a) mass = apoB–(Lp(a) mass * 0.16).¹
Table S2. Risk of aortic valve stenosis associated with natural log-transformed Lp(a) stratified by LDL-c levels.

| LDL-c group (mg/dL) | Unadj. HR (95% CI) | HR adj. for age and sex (95% CI) | HR adj. for age, sex and CAD (95% CI) |
|---------------------|---------------------|----------------------------------|--------------------------------------|
| LDL-c < 160         | 1.217 (1.058-1.399); p=0.006 | 1.189 (1.031-1.379); p=0.017 | 1.131 (0.983-1.300); p=0.085 |
| 160 ≥ LDL-c < 190   | 1.564 (1.289-1.898); p<0.001 | 1.569 (1.284-1.916); p<0.001 | 1.444 (1.184-1.762); p<0.001 |
| LDL-c ≥ 190         | 1.178 (0.940-1.477); p=0.154 | 1.130 (0.901-1.416); p=0.290 | 1.090 (0.870-1.365); p=0.453 |

HR = Hazard ratio per unit increase of natural log-transformed Lp(a) levels.
Figure S1. Risk of aortic valve stenosis incidence associated with quartiles of apoB/apoA-I ratio and Lp(a).

**Risk of aortic valve stenosis per quartiles**

**ApoB/apoA-I ratio quartiles**

Unadjusted
- Q1 (< 0.51)
- Q2 (0.51 - 0.62)
- Q3 (0.63 - 0.75)
- Q4 (≥ 0.75)

Adj. for age and sex
- Q1
- Q2
- Q3
- Q4

Adj. for CAD
- Q1
- Q2
- Q3
- Q4

**Lp(a) quartiles**

Unadjusted
- Q1 (< 7 mg/dL)
- Q2 (7 - 11)
- Q3 (12 - 27)
- Q4 (≥ 28)

Adj. for age, sex and LDL-c
- Q1
- Q2
- Q3
- Q4

Adj. for age, sex, LDL-c and CAD
- Q1
- Q2
- Q3
- Q4

Multivariate Cox proportional hazards analysis for AVS incidence. Q = quartile; LDL-c = low-density lipoprotein cholesterol; CAD = concomitant coronary artery disease.
Figure S2. Risk of aortic valve stenosis incidence associated with corrected apoB/apoA-I.

| Subgroup | No. of participants (%) |
|----------|-------------------------|
| **ApoB corrected for Lp(a)/apoA-I ratio** | |
| Overall | 17745 (100%) |
| Age | |
| ≤ 59 | 8872 (50%) |
| > 59 | 8873 (50%) |
| ≤ 67 | 13309 (75%) |
| > 67 | 4436 (25%) |
| Sex | |
| Male | 7959 (45%) |
| Female | 9786 (55%) |
| CAD | |
| No | 13866 (78%) |
| Yes | 3879 (22%) |

Hazard ratio per SD increase in apoB/apoA-I ratio

Multivariate Cox proportional hazards analysis for AVS incidence. CAD = concomitant coronary artery disease; SD = standard deviation.
Supplemental Reference:

1. Enkhmaa B, Anuurad E, Zhang W, Berglund L. Significant associations between lipoprotein(a) and corrected apolipoprotein b-100 levels in african-americans. *Atherosclerosis*. 2014;235:223-229.